The Dec 19 half year report says that CGB bought 80% of the IP of a few "unique medicinal cannabis formulations" from a director for 50 million shares. Now that the coffers are overflowing, perhaps CGB will buy the remaining 20% for an even higher consideration?
" Subject to regulatory approvals CGB intends to investigate raising money directly into PMRPL with the view to independently list PMRPL on the ASX in 2020." Now that WILL be interesting.
CGB Price at posting:
1.0¢ Sentiment: None Disclosure: Not Held